MannKind's Q3 '25 Earnings Exceed Estimates with $0.07 Non-GAAP EPS and $82.13mln Revenue

MannKind Corporation (MNKD) reported Q3 2025 non-GAAP EPS of $0.07, beating estimates by $0.04, and revenue of $82.13 million, also beating expectations. The company's ReadyFlow Autoinjector for heart failure patients is a potential game-changer in the market. The autoinjector is designed to provide a quick and easy way for patients to administer medication, which can be especially important for those with heart failure who may have difficulty using traditional injection methods. With its innovative design and potential to improve patient outcomes, the ReadyFlow Autoinjector is an exciting development in the field of heart failure treatment.